




🚨 Could treating less and resting more be the key to smarter #cancer therapies? 💡💊 Our latest preprint shows how math models can shape intermittent therapies to exploit cancer #persisters and achieve better outcomes. 🔗 read here: biorxiv.org/content/10.1101/… @SPCGgroup @Simopompei

Optimal treatment for drug-induced cancer persisters involves release periods and intermediate drug doses biorxiv.org/content/10.1101/…

How do mutation rates compare across mammals, fishes, birds and reptiles? New work in @Nature finds: 1. Higher mutation rates in males in mammals & birds, but not in reptiles & fishes. 2. Generation time, age at maturity & fecundity affect mutation rates. nature.com/articles/s41586-0…

New @SPCGgroup preprint: Metacommunity structure preserves genome diversity in the presence of gene-specific selective sweeps. With @Simopompei @jacrickets @joshuasweitz bioRxiv doi.org/10.1101/2023.01.17.5…

@SPCGgroup preprint: a fitness trade-off explains the early fate of yeast aneuploids with chromosome gains. The fitness landscape includes a specific advantage and a chromosome length-specific cost - with @Simopompei bioRxiv doi.org/10.1101/2022.07.07.4…

Our web site is on line! spcg.unimi.it/

Almost 80 years ago, Luria and Delbrück measured mutation rate in bacteria. Today, in collaboration with @IFOMresearch Lagomarsino we adapted their assay to measure mutation rates before and under treatment in cancer cells. Find out more on @NatureGenet nature.com/articles/s41588-0…



Anonymous peer review x.com/eliistender10/status/1…

Lab meeting when you don’t have new results

@BardelliLab geneticists and @IFOMresearch LagomarsinoLab physicists together against cancer. With a new Luria-Delbrück assay we found that drug-induced persister cells increase their mutation rate during anticancer therapy. More @biorxivpreprint: biorxiv.org/cgi/content/shor…